ABSTRACT
Description: Bioclate consists of a recombinant human coagulation factor VIII, the recombinant antihemophilic factor (rAHF). It appears to be identical to the product Recombinate, marketed by Baxter. It is produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. It is provided as a lyophilized powder (containing 250, 500, or 1000 IU factor VIII activity per vial) to be reconstituted before intravenous administration.
